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Background: Advances in immunosuppression after kidney transplantation have
decreased the inﬂuence of early acute rejection (EAR) on graft survival. Several
studies have suggested that late acute rejection (LAR) has a poorer effect on long-
term graft survival than EAR. We investigated whether the timing of acute rejection
(AR) inﬂuences graft survival, and analyzed the risk factors for EAR and LAR.
Methods: We performed a retrospective cohort study involving 709 patients who
underwent kidney transplantation between 2000 and 2009 at the Samsung Medical
Center, Seoul, Korea. Patients were divided into three groups: no AR, EAR, and LAR. EAR
and LAR were deﬁned as rejection before 1 year and after 1 year, respectively. Differences
in graft survival between the three groups and risk factors of graft failure were analyzed.
Results: Of the 709 patients, 198 (30%) had biopsy-proven AR [EAR¼152 patients (77%);
LAR¼46 patients (23%)]. A total of 65 transplants were lost. The 5-year graft survival rates
were 97%, 89%, and 85% for patients with no AR, EAR, and LAR, respectively. These
differences were signiﬁcant (Po0.001 for both by log-rank test). In time-dependent Cox
regression analysis, EAR (hazards ratio, 3.37; 95% conﬁdence interval, 1.90–5.99) and LAR
(hazards ratio, 5.32; 95% conﬁdence interval, 2.65–10.69) were signiﬁcantly related to
graft failure. When we set LAR as standard and compared it with EAR, there was no
statistical difference between EAR and LAR (P¼0.21).
Conclusion: AR, regardless of its timing, signiﬁcantly worsened graft survival. Treatments
to reduce the incidence of AR and improve prognosis are needed.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It has been demonstrated that an acute rejection (AR)
episode is a major risk factor of graft loss. However, not all
rejection episodes have the same effect. Severity of rejection,15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
, Department of Medicine,
ersity School of Medicine,
orea.
(W Huh).as described using the Banff system, timing of rejection as
early (EAR) or late acute rejection (LAR), and whether the
allograft recovers to the baseline function after rejection are
known to affect the long-term graft outcome.
Several studies have evaluated the difference between EAR and
LAR in terms of impact on long-term graft survival. Some studies
have suggested that LAR has a poorer effect on long-term graft
survival than EAR [1–3], and recent studies showed that EAR was
not the cause of graft failure [4,5]. It has been proposed that
differences in immunologic activity and triggering factors such ashrology. Published by Elsevier. This is an open access article under the
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may be the reasons for these distinctions [2,5].
Rates of AR and graft survival have steadily improved over
time, but AR still occurs frequently and is a major risk factor
for graft failure. Although several studies have compared EAR
and LAR, we realized that the deﬁnitions of AR and the criteria
for EAR and LAR varied across these studies. It is important to
know the prognosis of AR to determine the treatment strategy
and to improve the graft outcome. The aim of the present
study was to identify whether the timing of AR inﬂuences graft
survival and to analyze the risk factors for EAR and LAR.Methods
Patients
We performed a retrospective cohort study involving 709
patients who underwent kidney transplantation between 2000
and 2009 at the Samsung Medical Center, Seoul, Korea. Follow-
up lasted until June 2011. Indication of transplanted kidney
biopsy was when acute or chronic renal allograft rejection is
suspected. The main clinical indicator of rejection is a trend
toward increasing serum creatinine level above baseline.
Besides, other clinical indicators such as oliguria or proteinuria
not related to glomerulonephritis could be an indication of
biopsy depending on the clinical situation. Protocol biopsy was
not performed in our study period. We used initial biopsy
displaying AR to deﬁne EAR and LAR. EAR and LAR were
deﬁned as rejection before 1 year and after 1 year, respectively.
Patients were divided into three groups: no AR, EAR, and LAR.
The standard immunosuppression regimen consisted of pre-
dnisolone and cyclosporine or tacrolimus plus mycophenolic
acid or azathioprine. Recipients younger than 18 years,
patients with multiple organ transplants (e.g., kidney and liver,
or kidney and pancreas), repeated kidney transplantation, pri-
mary nonfunctioning transplants, follow-up loss, and death with
a functioning graft were excluded. There were ﬁve patients who
had both EAR and LAR. We included them in the LAR group
considering that EAR could be a risk factor of LAR.
Deﬁnition
AR was deﬁned clinically by an acute deterioration in
allograft function and conﬁrmed with tissue diagnosis. Banff
borderline AR was not considered as an AR episode. Graft
failure was deﬁned as transplant nephrectomy, retransplanta-
tion, or return to long-term dialysis. Delayed graft function
was deﬁned as the need for dialysis in the 1st week.
Statistical analysis
The clinical characteristics of the groups without AR, with
EAR, and with LAR were compared using the chi-square test or
the Fisher exact test. Where there were signiﬁcant differences
between the three groups, we compared two groups. For
statistical comparisons between the means from different
groups, we used the Kruskal–Wallis test. Multinomial logistic
regression analysis was performed to determine the predictive
values of EAR and LAR. Recipient age, sex, body mass index,
underlying diabetes, preformed panel-reactive lymphocyto-
toxic antibodies (PRAs), induction protocol, dialysis duration,
human leucocyte antigen (HLA) mismatches, cold ischemictime, immunosuppressive regimens, donor age, donor type,
and donor gender were used for the univariable analysis.
Variables with a value of Po0.2 in either the EAR or LAR
groups in the univariable analysis were selected for the multi-
variable analysis. The graft survival rates of the three groups
were compared using time-dependent Cox regression analysis.
Univariable and multivariable analyses were performed to
evaluate the predictive factors of graft survival; age, gender,
body mass index, underlying diabetes, PRA, induction protocol,
dialysis duration, HLA mismatches, cold ischemic time, immu-
nosuppressive regimens, donor age, donor type, and donor
gender were used as variables. Signiﬁcant predictors
(P value o0.2) of graft survival in the univariable analysis
were ﬁtted into a multivariable model. The results are pre-
sented as hazard ratios (HRs) with 95% conﬁdence interval (CI).
The P values were corrected using the Bonferroni method
because of multiple testing. A value of Po0.05 was considered
to be signiﬁcant. Statistical analysis was executed using SPSS
for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA).Results
Study population
In total, 709 patients were included in the analysis. Of
these, 198 (28%) had biopsy-proven AR, 152 (21%) had EAR, 46
(7%) had LAR, and 511 (72%) did not have a rejection episode.
Demographic characteristics of the patient population studied
are listed in Table 1.
Recipient sex and age, dialysis duration, positive PRA
(430%), HLA mismatches, and donor type were signiﬁcantly
different between the three groups. Patients with EAR were
more likely to be male than the no AR group (Po0.001) and
LAR group (Po0.001). Patients with LAR were more likely
to be PRA positive than the no AR group (P¼0.01) and EAR
(P¼0.01) group. The no AR group had more HLA-A, HLA-B, and
HLA-DR complete matches than the EAR group (Po0.001).
The proportion of living donors was higher in the EAR group
than in the no AR group (P¼0.003). The LAR group was
younger than the no AR group (P¼0.03). The EAR group had
a short dialysis duration than the no AR group (P¼0.05).
Graft survival
Allograft failure occurred in 65 patients. The 5-year graft
survival rates were 97%, 89%, and 85% for patients with no AR,
EAR, and LAR, respectively (Fig. 1). The patients with EAR or
LAR showed lower graft survival rates than those with no AR
(Po0.001 for both by log-rank test). The graft survival rates
were not different between the EAR group and LAR group
(P¼0.22 by log-rank test).
Risk proﬁle of EAR and LAR
In univariable analysis, EAR was related to male sex, HLA
mismatch, living donor, and short cold ischemic time. The
variable predictive of LAR was young recipient age and positive
PRA (Table 2). By multivariable analysis, EAR was related to
male sex [odds ratio (OR), 1.89, 95% CI, 1.18–3.00], HLA
mismatch (OR, 12.27; 95% CI, 2.46–64.19), and older donor
age (OR, 1.02; 95% CI, 1.00–1.04). LAR was associated with
Table 1. Characteristics of the study population
No AR
(n¼511)
EAR
(n¼152)
LAR
(n¼46)
P
Recipient age (y) 42 (34–50)n 41 (31–48) 36 (31–47)n 0.02
Male recipient 267 (52)† 104 (68)†,‡ 17 (37)‡ o0.001
Recipient BMI (kg/m2) 22 (20–25) 23 (20–25) 22 (20–25) 0.06
Diabetes 73 (14) 20 (13) 6 (13) 0.92
Dialysis duration (mo) 15 (3–53)§ 9 (2–34)§ 19 (5–51) 0.03
PRA 430% 32 (6)|| 7 (5)¶ 8 (17)||,¶ 0.008
HLA—no mismatch 67 (13)nn 2 (1)nn 1 (1) o0.001
Deceased donor 125 (25)†† 18 (12)†† 10 (22) 0.004
Donor age (y) 40 (31–47) 42 (33–50) 42 (33–50) 0.15
Male donor 280 (55) 82 (54) 30 (65) 0.37
Cold ischemic time (min) 65 (48–155) 62 (45–87) 70 (52–121) 0.08
Induction 155 (30) 34 (22) 17 (37) 0.08
Immunosuppression
CsA 237 (46) 75 (49) 22 (48) 0.78
FK 269 (53) 74 (49) 24 (52)
Delayed graft function 25 (5) 6 (4) 4 (9) 0.43
Cellular rejection
Banff grade IA 79 (52) 23 (50) 0.37
IB 27 (18) 14 (30)
IIA 28 (18) 6 (13)
IIB 6 (4) 1 (2)
Antibody-mediated rejection 12 (8) 2 (4) 0.40
n No AR vs. LAR, P ¼ 0.03. † No AR vs. EAR, P o0.001. ‡ EAR vs. LAR, P o0.001. § No AR vs. EAR, P ¼ 0.05. || No AR vs. LAR, P ¼ 0.01. ¶ EAR vs. LAR,
P ¼ 0.01. nn No AR vs. EAR, P o0.001. †† No AR vs. EAR, P ¼ 0.003.
Data are presented as n (%) or median (interquartile range 25–75%).
By multiple testing, P value was corrected with the Bonferroni method.
CsA, cyclosporine; EAR, early acute rejection; FK, tacrolimus; HLA, human leucocyte antigen; LAR, late acute rejection; No AR, no acute rejection; PRA,
panel-reactive lymphocytotoxic antibody.
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Figure. 1. Kaplan–Meier graft survival for transplants without AR,
with EAR, and with LAR. AR, acute rejection; EAR, early acute rejection;
LAR, late acute rejection.
Kidney Res Clin Pract 34 (2015) 160–164162younger recipient age (OR, 0.95; 95% CI, 0.91–0.98) and
positive PRA (OR, 2.72; 95% CI, 1.20–10.48) (Table 2).Graft failure risk factor
Univariable and multivariable Cox regression analyses were
used to identify independent variables associated with poor
transplant outcomes. Rejection was regarded as a time-
dependent variable. In univariable analysis, EAR (HR, 3.27;
95% CI, 1.88–5.66), LAR (HR, 5.10; 95% CI, 2.59–10.08), longer
dialysis duration (HR, 1.01; 95% CI, 1.00–1.00), and deceased
donor (HR, 1.84; 95% CI, 1.02–3.31) were signiﬁcant risk factors
for graft failure.In multivariable analysis, EAR (HR, 3.37; 95% CI, 1.90–5.99)
and LAR (HR, 5.32; 95% CI, 2.65–10.69) were signiﬁcantly
related to graft failure (Table 3). When we set LAR as standard
and compared it with EAR, there were no statistical difference
between EAR and LAR (P ¼ 0.21).Discussion
In this study, we found that EAR, as well as LAR, had
negative effects on long-term graft survival. In a time-
dependent Cox regression test to evaluate the risk factors for
graft survival, both EAR and LAR were signiﬁcant risk factors
for graft failure compared with the no AR group. Unlike other
studies that showed that EAR was not the cause of graft failure,
EAR was a signiﬁcant risk factor for graft failure in our study
[4,5]. Recently, El Ters et al [6] showed that early acute cellular
rejection was not a single acute event but triggered a persis-
tent alloimmune response that might result in long-term graft
injury and graft loss years after the acute event. These ﬁndings
are consistent with our observation.
Many studies have been conducted to explore whether the
timing of AR affects graft survival. The majority of these
studies reported that LAR was correlated with poor long-
term graft survival [1–3]. However, reports about the impact
of EAR are inconsistent. We thought that the reason for
variable results might be that each study used different
methods and populations, with the cutoff for EAR being
particularly variable. Some studies used a 3-month cutoff to
divide EAR and LAR [1,3]. Others used 6- or 12-month cutoffs
[7,8]. Most studies categorized EAR and LAR by the onset of the
ﬁrst AR [1,2]. One study used the timing of the last treated AR
[3]. Deﬁnitions of AR were also inconsistent. Some studies
included AR diagnosed using clinical biopsy or using either
Table 2. Logistic regression model for predicting EAR and LAR
Univariable analysis Multivariable analysis
EAR LAR EAR LAR
Exp(B) P 95% CIn Exp(B) P 95% CIn Exp(B) P 95% CI n Exp(B) P 95% CIn
Recipient age 0.99 0.29 0.97–1.01 0.96 0.01 0.92–0.99 0.99 0.26 0.96–1.01 0.95 0.002 0.91–0.98
Male recipient 1.98 o0.001 1.28–3.07 0.54 0.10 0.26–1.09 1.89 0.004 1.18–3.00 0.59 0.23 0.27–1.26
BMI 1.06 0.06 0.99–1.12 0.96 0.81 0.86–1.07 1.05 0.18 0.99–1.12 0.99 0.75 0.89–1.12
Diabetes 0.91 0.73 0.50–1.67 0.81 0.82 0.32–2.50
Dialysis duration 0.99 0.07 0.99–1.00 1.00 0.89 0.99–1.00 0.99 0.65 0.99–1.00 1.00 40.99 0.99–1.01
PRA 430% 0.63 0.90 0.28–1.89 3.15 0.02 1.20–8.26 1.16 40.99 0.41–3.23 3.54 0.02 1.20–10.48
HLA mismatchZ1 11.3 0.002 2.24–57.32 6.79 0.12 0.69–66.73 12.55 0.002 2.46–64.19 8.38 0.08 0.83–84.94
Deceased donor 0.42 0.002 0.23–0.76 0.86 0.68 0.37–1.98 0.81 40.99 0.26–2.52 0.71 40.99 0.14–3.54
Donor age 1.02 0.11 1.00–1.03 1.01 0.65 0.98–1.04 1.02 0.05 1.00–1.04 1.02 0.54 0.99–1.05
Male donor 0.97 40.99 0.64–1.46 1.55 0.35 0.75–3.18.
Cold ischemic time 0.99 0.002 0.99–1.00 0.99 0.68 1.00–1.00 1.00 0.08 0.99–1.00 1.00 0.88 0.99–1.00
Induction 0.66 0.11 0.41–1.08 1.35 0.71 0.66–2.76 1.19 40.99 0.58–2.44 2.02 0.27 0.71–5.78
FK (vs. CsA) 0.87 0.47 0.61–1.26 0.97 0.91 0.53–1.77
Delayed graft function 0.80 40.99 0.28–2.26 0.83 0.55 0.53–6.53
n 95% CI for odds ratio was corrected with the Bonferroni method because of multiple testing.
BMI, body mass index; CI, conﬁdence interval; CsA, cyclosporine; EAR, early acute rejection; FK, tacrolimus; HLA, human leucocyte antigen; LAR, late
acute rejection; PRA, panel-reactive lymphocytotoxic antibody.
Table 3. Univariable and multivariable analyses of risk factors associated with graft survival
Univariable analysis Multivariable analysis
Hazard ratio 95% CI P Hazard ratio 95% CI P
Rejection
(vs. No AR)
EAR 3.27 1.88–5.66n o0.001 3.37 1.90–5.99n o0.001
LAR 5.10 2.59–10.08n o0.001 5.32 2.65–10.69n o0.001
Recipient age 0.99 0.97–1.02 0.39
Male recipient 1.22 0.74–2.00 0.47
Diabetes 1.47 0.82–3.18 0.17 1.60 0.80–3.18 0.18
Dialysis duration 1.01 1.00–1.01 0.04 1.00 1.00–1.01 0.27
PRA 430% 1.05 0.33–3.36 0.94
HLA mismatchZ1 3.63 0.89–14.85 0.07 2.11 0.51–8.79 0.31
Deceased donor 1.84 1.02–3.31 0.04 1.54 0.54–4.43 0.42
Donor age 1.02 1.00–1.04 0.08 1.02 0.99–1.04 0.15
Male donor 1.18 0.72–1.92 0.52
Cold ischemic time 1.00 1.00–1.00 0.18 1.00 1.00–1.00 0.81
Induction 1.41 0.75–2.66 0.29
FK (vs. CsA) 1.27 0.77–2.09 0.36
Delayed graft function 1.43 0.45–4.57 0.55
n 95% CI for odds ratio was corrected with the Bonferroni method because of multiple testing.
AR, acute rejection; CI, conﬁdence interval; CsA, cyclosporine; EAR, early acute rejection; FK, tacrolimus; HLA, human leucocyte antigen; LAR, late
acute rejection; PRA, panel-reactive lymphocytotoxic antibody.
Koo et al / Early acute rejection in kidney transplantation 163clinical or protocol biopsy [5]. Others used clinical AR that was
not biopsy proven [3,7]. Study populations also differed; some
studies selected only deceased-donor kidney transplants
[1–3], whereas others enrolled both living- and deceased-donor
kidney transplants [5,6].
In this study, AR was diagnosed using clinical biopsy. We
excluded the Banff borderline to overcome the bias from mis-
diagnosis [9]. The 1-year cutoff was used. Although it was
arbitrary from 3-month to 1-year cutoff, we could identify the
inﬂection points at 1 year on the Kaplan–Meier curve of AR
(Fig. 2). There were ﬁve patients who had experienced both EAR
and LAR. In consideration of the EAR as a risk factor of LAR, we
included them to the LAR group. When we put them into either
the EAR group or excluded them, their inﬂuence on the study
results was statistically insigniﬁcant (data not shown). Because AR
is a time-dependent variable and not a baseline characteristic, the
effect of rejection on survival is not constant over time. We chosethe time-dependent Cox regression test for survival analysis,
which could be more appropriate than the Kaplan–Meier esti-
mate or Cox regression analysis, and found that EAR and LAR
were independent risk factors for graft survival.
We found that EAR was associated with male sex, HLA
mismatch, and older donor. LAR was associated with young
recipient age and positive PRA. HLA mismatches are well-
known risk factors for AR. HRs in the range of 1.39–3.78 have
been described for one or more HLA-A, HLA-B, and HLA-DR
mismatches [10]. Older donor and positive PRA are also known
risk factors for AR [11]. Older donor age is known to be related
to inﬂammation in grafts, which is associated with later
chronic graft damage [12]. The association of young recipient
age and LAR could be partly explained by noncompliance or
increased immune responsiveness [3,5]. In our study, male sex
was associated with EAR. Evidence for the effect of sex is by no
means consistent in many studies [13,14].
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Figure 2. Kaplan–Meier plot of the cumulative incidence of acute
rejection.
Kidney Res Clin Pract 34 (2015) 160–164164There were several limitations of this investigation. First,
the study was retrospective, and association does not prove
causality. Second, antibody-mediated rejection (AMR) was not
included as a graft failure risk factor, although it has been
identiﬁed as the cause of graft failure in many studies [5,7,8].
Because the Banff 2001 classiﬁcation included criteria for AMR,
AMR has been increasingly recognized. In the early study
period, distinguishing AMR from acute cellular rejection was
not precise. This is one reason why the incidence of AMR in
our study was lower than that of the published data [5]. In
addition, it was difﬁcult to show the statistical difference
because the number of events was small. Third, clinical factors,
such as recovery from AR and type of treatment, were not
included in the analysis. These may be different because of the
timing of AR and could inﬂuence graft survival rates. As a
retrospective study, determining recovery from AR through
a chart review has the risk of bias. Additional prospective
studies with recent data to carefully distinguish AMR through
microcirculation inﬂammation and C4d staining could show
clearer results.
The study is signiﬁcant in two main ways. First, the EAR and
LAR categories were clearly deﬁned. All AR episodes were
conﬁrmed with biopsy. If we had included clinical rejection,
the incidence of AR would be overestimated. Furthermore, we
recognized the patients who had both EAR and LAR, included
them in each group, and excluded them to see if there is a
statistical difference in each cases. Second, the study empha-
sizes that the risk of EAR on graft survival is of importance.
Nowadays, EAR is thought to be of no particular importance in
graft survival. Because of the side effects of immunosuppres-
sants, a reduction in medication is a positive trend in the
management of EAR, but EAR is still a signiﬁcant risk factor for
graft failure.
In conclusion, these observations suggest that we should
still consider EAR to be a major barrier to improving long-term
graft survival. Graft biopsy, either clinical biopsy or protocol
biopsy, has been the gold standard for diagnosing EAR. How-
ever, it is invasive and cannot predict AR. For the prevention
and early detection of EAR, a noninvasive immunologic mon-
itoring method should be developed. Major histologic types
of LAR may include AMR [5]. At this time, education fornoncompliant patients is important in the prevention of AMR.
The development of a noninvasive immunologic monitoring
method is also necessary for early detection.Conﬂicts of interest
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